

Osiris Therapeutics, Inc. (OSIR) - Financial and Strategic SWOT Analysis Review

Description: Osiris Therapeutics, Inc. (OSIR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Osiris Therapeutics, Inc. (Osiris) is a biotechnology company engaged in research, development and commercialization of stem cell products for the treatment of conditions related to wound, orthopedic, and sports medicine. The company operates through its biosurgery business segment develops new products related to diabetic foot ulcers, venous stasis ulcers, dermal burns, and sports medicine products for motion preservation. The product portfolio of the company includes commercialized products, Grafix, Ovation, OvationOS and Cartiform. The company is headquartered in Columbia, the US.

Osiris Therapeutics, Inc. Key Recent Developments

Mar 26, 2014: Osiris Therapeutics Announces Therésa K. Dixon as General Manager of Market Access and Reimbursement
Mar 11, 2014: Osiris Therapeutics Reports Change in Tax Benefit Allocation for Fourth Quarter and Full Year 2013 Financial Results
Mar 05, 2014: Osiris Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results: For the Full Year, Revenue Increased 3-Fold, Company was Profitable and Ended with Assets of \$92.0 Million
Feb 12, 2014: Osiris Therapeutics Promotes Frank Czworka to Vice President and General Manager of Wound Care
Jan 14, 2014: Osiris Therapeutics Board Confirms Lode Debrabandere, PhD, MBA, as President and Chief Executive Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 - About the Company
Osiris Therapeutics, Inc. - Key Facts
Osiris Therapeutics, Inc. - Key Employees
Osiris Therapeutics, Inc. - Key Employee Biographies
Osiris Therapeutics, Inc. - Major Products and Services
Osiris Therapeutics, Inc. - Pharmaceutical Pipeline Products Data
Osiris Therapeutics, Inc., Pipeline Products by Therapy Area
Osiris Therapeutics, Inc., Pipeline Products by Development Phase
Osiris Therapeutics, Inc. - Medical Equipment Pipeline Products Data
Osiris Therapeutics, Inc. Pipeline Products by Equipment Type
Osiris Therapeutics, Inc. Pipeline Products by Development Stage
Osiris Therapeutics, Inc. - History
Osiris Therapeutics, Inc. - Company Statement
Osiris Therapeutics, Inc. - Locations And Subsidiaries
Head Office
Section 2 – Company Analysis
Osiris Therapeutics, Inc. - Business Description
Osiris Therapeutics, Inc. - SWOT Analysis
SWOT Analysis - Overview
Osiris Therapeutics, Inc. - Strengths
Strength - Technology and Manufacturing Process
Strength - Intellectual Property Portfolio
Strength - Emphasis on Research
Osiris Therapeutics, Inc. - Weaknesses
Weakness - Discontinued Project
Osiris Therapeutics, Inc. - Opportunities
Opportunity - Product Pipeline
Opportunity - Strategic Initiatives
Opportunity - Orphan Drug Designation
Osiris Therapeutics, Inc. - Threats
Threat - Rapid Technological Advancements
Threat - Stringent Government Regulation
Threat - Competitive Landscape
Osiris Therapeutics, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company's Lifesciences Financial Deals and Alliances

Osiris Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014

Osiris Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014

Osiris Therapeutics, Inc., Medical Equipment, Deals By Year, 2008 to YTD 2014

Osiris Therapeutics, Inc., Medical Equipment, Deals By Type, 2008 to YTD 2014

Osiris Therapeutics, Inc., Recent Deals Summary

Section 5 – Company's Recent Developments

Osiris Therapeutics, Inc., Recent Developments

Mar 26, 2014: Osiris Therapeutics Announces Therésa K. Dixon as General Manager of Market Access and Reimbursement

Mar 11, 2014: Osiris Therapeutics Reports Change in Tax Benefit Allocation for Fourth Quarter and Full Year 2013 Financial Results

Mar 05, 2014: Osiris Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results: For the Full Year, Revenue Increased 3-Fold, Company was Profitable and Ended with Assets of \$92.0 Million

Feb 12, 2014: Osiris Therapeutics Promotes Frank Czworka to Vice President and General Manager of Wound Care

Jan 14, 2014: Osiris Therapeutics Board Confirms Lode Debrabandere, PhD, MBA, as President and Chief Executive Officer

Dec 02, 2013: Osiris Therapeutics Announces Leadership Transition

Nov 29, 2013: Osiris provides update on proposed ruling by CMS

Nov 25, 2013: Osiris Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference

Nov 01, 2013: Osiris Reports 3rd Quarter 2013 Results: Revenue Up 220%, Strong Balance Sheet, Profitable and Now Cash Flow Positive from Continuing Operations

Oct 22, 2013: Bronstein, Gewirtz & Grossman Announces Investigation of Osiris Therapeutics

Section 6 – Appendix

Methodology

Ratio Definitions

About Us

Contact Us

Disclaimer

List of Tables

Osiris Therapeutics, Inc., Key Facts

Osiris Therapeutics, Inc., Key Employees

Osiris Therapeutics, Inc., Key Employee Biographies

Osiris Therapeutics, Inc., Major Products and Services

Osiris Therapeutics, Inc., Number of Pipeline Products by Therapy Area

Osiris Therapeutics, Inc., Number of Pipeline Products by Development Stage

Osiris Therapeutics, Inc., Pipeline Products By Therapy Area and Development Phase

Osiris Therapeutics, Inc. Number of Pipeline Products by Equipment Type

Osiris Therapeutics, Inc. Pipeline Products by Equipment Type

Osiris Therapeutics, Inc. Number of Pipeline Products by Development Stage

Osiris Therapeutics, Inc. Pipeline Products by Development Stage

Osiris Therapeutics, Inc., History

Osiris Therapeutics, Inc., Key Competitors

Osiris Therapeutics, Inc., Ratios based on current share price

Osiris Therapeutics, Inc., Annual Ratios

Osiris Therapeutics, Inc., Interim Ratios

Osiris Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014

Osiris Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014

Osiris Therapeutics, Inc., Medical Equipment, Deals By Year, 2008 to YTD 2014

Osiris Therapeutics, Inc., Medical Equipment, Deals By Type, 2008 to YTD 2014

Osiris Therapeutics, Inc., Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Osiris Therapeutics, Inc., Pipeline Products by Therapy Area
Osiris Therapeutics, Inc., Pipeline Products by Development Phase
Osiris Therapeutics, Inc. Pipeline Products by Equipment Type
Osiris Therapeutics, Inc. Pipeline Products by Development Stage
Osiris Therapeutics, Inc., Performance Chart (2009 - 2013)
Osiris Therapeutics, Inc., Ratio Charts
Osiris Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Osiris Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Osiris Therapeutics, Inc., Medical Equipment, Deals By Year, 2008 to YTD 2014
Osiris Therapeutics, Inc., Medical Equipment, Deals by Type, 2008 to YTD 2014

Ordering:

Order Online - <http://www.researchandmarkets.com/reports/1883597/>

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

<http://www.researchandmarkets.com/contact/>

Order Information

Please verify that the product information is correct and select the format(s) you require.

Product Name: Osiris Therapeutics, Inc. (OSIR) - Financial and Strategic SWOT Analysis Review
Web Address: <http://www.researchandmarkets.com/reports/1883597/>
Office Code: SCUUW1IS

Product Formats

Please select the product formats and quantity you require:

	Quantity
Electronic (PDF) - Single User:	<input type="checkbox"/> EUR 102
Electronic (PDF) - Site License:	<input type="checkbox"/> EUR 204
Electronic (PDF) - Enterprisewide:	<input type="checkbox"/> EUR 307

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐

First Name: _____ Last Name: _____

Email Address: * _____

Job Title: _____

Organisation: _____

Address: _____

City: _____

Postal / Zip Code: _____

Country: _____

Phone Number: _____

Fax Number: _____

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)

Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:☐ American Express☐ Diners Club☐ Master Card☐ Visa

Cardholder's Name _____

Cardholder's Signature _____

Expiry Date _____ | _____

Card Number _____

CVV Number _____

Issue Date _____ | _____

(for Diners Club only)

☐ Pay by check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:

Please transfer funds to:

Account number	833 130 83
Sort code	98-53-30
Swift code	ULSBIE2D
IBAN number	IE78ULSB98533083313083
Bank Address	Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at <http://www.researchandmarkets.com/info/terms.asp>

Please fax this form to:**(646) 607-1907 or (646) 964-6609 - From USA****+353-1-481-1716 or +353-1-653-1571 - From Rest of World**